9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys

AIDS

Volumn 5, Issue 1, 1991, Pages 21-28

  Balzarini, Jan ^a   Naesens, Lieve ^a   Slachmuylders, Jan ^b   Niphuis, Henk ^b   Rosenberg, Ivan ^c   Holý, Anthony ^c   Schellekens, Huub ^b   Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b TNO   (Netherlands)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

9 (2 Phosphonylmethoxyethyl)adenine (PMEA); AIDS; Simian immunodeficiency virus (SIV)

Indexed keywords

ADEFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INHIBITION; VIRUS REPLICATION;

ADENINE; ANIMAL; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELL LINE; HIV ENVELOPE PROTEIN GP120; HUMAN; MACACA MULATTA; MOLECULAR STRUCTURE; RETROVIRIDAE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIV; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION; VIRUS REPLICATION;

EID: 0025979184     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199101000-00003     Document Type: Article

References (32)

1. BARRÉ-SINOUSSI F, CHERMANN JC, REY R, ET AL.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science 1983, 220:868-871.
2. GALLO RC, SALAHUDDIN SZ, POPOVIC M, ET AL.: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224:500-503.
3. BRODER S, YARCHOAN R, COLLINS JM, ET AL.: Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet 1985, ii:627-630.
4. YARCHOAN R, BRODER S. Anti-retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides. Pharm Ther 1989, 40:329-348.
5. YARCHOAN R, KLECKER RW, WEINHOLD KJ, ET AL.: Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986, i:575-580.
6. YARCHOAN R, BERG G, BROUWERS P, ET AL.: Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1987, i:132-135.
7. FISCHL MA, RICHMAN DD, GRIECO MH, ET AL.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987, 317:185-191.
8. YARCHOAN R, PERNO CF, THOMAS RV, ET AL.: Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988, i:76-81.
9. CRUMPACKER C, HEAGY W, BUBLEY G, ET AL.: Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). Ann Intern Med 1987, 107:664-674.
10. ABRAMS DI, KUNO S, WONG R, ET AL.: Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989, 110:183-188.
11. RICHMAN DD, FISCHL MA, GRIECO MH, ET AL.: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987, 317:192-197.
12. DE CLERCQ E, HOLY A, ROSENBERG I, SAKUMA T, BALZARINI J, MAUDGAL PC: A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323:464-467.
13. PAUWELS R, BALZARINI J, SCHOLS D, ET AL.: Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 1988, 32:1025-1030.
14. BALZARINI J, NAESENS L, HERDEWIJN P, ET AL.: Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl) adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989, 86:332-336.
15. GANGEMI JD, COZENS RM, DE CLERCQ E, BALZARINI J, HOCHKEPPEL HK: 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. An timicrob Agents Chemother 1989, 33:1864-1868.
16. EGBERINK HF, BORST MAJ, NIPHUIS H, ET AL.: Inhibition of feline lentivirus infection by 9-(2-phosphonylmethoxyethyl) adenine. Proc Natl Acad Sci USA 1990, 87:3087-3091
17. BRONSON JJ, GHAZZOULI I, HITCHCOCK MJM, KERN ER, MARTIN JC: In vivo antiretrovirus and anti-cytomegalovirus activity of 9-((2-phosphonylmethoxy)ethyl)adenine PMEA. V International Conference on AIDS. Montreal, June 1989 [abstract M.C.P. 74].
18. DE CLERCQ E, HOLÝ A, ROSENBERG I: Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob Agents Chemother 1989, 33:185-191.
19. DANIEL MD, LETVIN NL, KING NW, ET AL.: Isolation of a T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985, 228:1201-1204.
20. KANNAGI M, YETZ JM, LETVIN NL: in vitro growth characteristics of simian T-lymphotropic virus type III. Proc Natl Acad Sci USA 1985, 82:7053-7057.
21. DANIEL MD, LETVIN NL, SEHGAL PK, ET AL.: Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol 1987, 68:3183-3189
22. HOLY A, ROSENBERG I: Synthesis of 9-(2-phosphonylmethoxyethyl)adenine and related compounds. Collect Czech Chem Commun 1987, 52:2801-2809.
23. POPOVIC M, SARNGADHARAN MG, READ E, GALLO RC: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224:497-500.
24. DE CLERCQ E, MERIGAN TC: Moloney sarcoma virus-induced tumors in mice: inhibition or stimulation by (poly rI):(poly rC). Proc Soc Exp Biol Med 1971, 137:590-594.
25. KORNFELD H, RIEDEL N, VIGLIANTI GA, HIRSCH V, MULLINS JI: Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature 1987, 326:610-613.
26. PEDERSON NC, HO EW, BROWN ML, YAMAMOTO JK: Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987, 235:790-793.
27. BALZARINI J, BABA M, PAUWELS R, HERDEWIJN P, DE CLERCQ E: Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem Pharmacol 1988, 37:2847-2856.
28. KLECKER RW, COLLINS JM, YARCHOAN R, THOMAS R, JENKINS JF: Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987, 41:407-412.
29. MCCLOSKEY SE, REGE AB, LERTORA JJL, GEORGE WJ, AGRAWALL KC: Zidovudine pharmacokinetics and plasma levels in patients with HIV infection. Clin Res 1988, 36:21A.
30. BALZARINI J, NAESENS L, DE CLERCQ E: Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. Int J Cancer 1990, 46:337-340.
31. NAESENS L, BALZARINI J, DE CLERCQ E: Single-dose administration of 9-(2-phosphonylmethoxyethyl)adnenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-dianinopurine (PMEADAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res (in press).
32. WATANABE M, REIMANN KA, DELONG PA, LIU T, FISHER RA, LETVIN NL: Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature 1989, 337:267-270.